Safety, Pharmacokinetics, and Pharmacodynamics of CC‐90001 (BMS‐986360), a c‐Jun N‐terminal Kinase Inhibitor, in Phase 1 Studies in Healthy Participants-Reference-Cited by-同舟云学术

Safety, Pharmacokinetics, and Pharmacodynamics of CC‐90001 (BMS‐986360), a c‐Jun N‐terminal Kinase Inhibitor, in Phase 1 Studies in Healthy Participants

Published:2022-10-18 Issue:12 Volume:11 Page:1394-1404
ISSN:2160-763X
Container-title:Clinical Pharmacology in Drug Development
language:en
Short-container-title:Clinical Pharm in Drug Dev

Author:

Ye Ying¹,Gaudy Allison¹,Thomas Michael¹,Reyes Josephine¹,Burkhardt Barbara¹,Horan Gerald¹,Liu Liangang¹,Chen Jian¹,Ghosh Atalanta¹,Carayannopoulos Leonidas N.¹,Tatosian Daniel A.¹,Palmisano Maria¹

Affiliation:

1. Bristol Myers Squibb Princeton New Jersey USA

Publisher

Wiley

Subject

Pharmacology (medical),Pharmaceutical Science

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cpdd.1178

Reference17 articles.

1. JNK Signaling: Regulation and Functions Based on Complex Protein-Protein Partnerships

2. The functional contrariety of JNK

3. Modulation of Hepatic Fibrosis by c-Jun-N-Terminal Kinase Inhibition

4. Constitutive ALK5-Independent c-Jun N-Terminal Kinase Activation Contributes to Endothelin-1 Overexpression in Pulmonary Fibrosis: Evidence of an Autocrine Endothelin Loop Operating through the Endothelin A and B Receptors

5. Activation and Dysregulation of the Unfolded Protein Response in Nonalcoholic Fatty Liver Disease

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. c-Jun N-terminal kinase signaling in aging;Frontiers in Aging Neuroscience;2024-08-29

2. Phase 2, Double-Blind, Placebo-controlled Trial of a c-Jun N-Terminal Kinase Inhibitor in Idiopathic Pulmonary Fibrosis;American Journal of Respiratory and Critical Care Medicine;2024-08-15

3. Safety, Pharmacokinetics, and Antifibrotic Activity of CC‐90001 (BMS‐986360), a c‐Jun N‐Terminal Kinase Inhibitor, in Pulmonary Fibrosis;Clinical Pharmacology in Drug Development;2023-06-28

4. Non-kinase targeting of oncogenic c-Jun N-terminal kinase (JNK) signaling: the future of clinically viable cancer treatments;Biochemical Society Transactions;2022-12-01